{
    "clinical_study": {
        "@rank": "11735", 
        "arm_group": {
            "arm_group_label": "TactiCath Quartz", 
            "arm_group_type": "Experimental", 
            "description": "TactiCath Quartz treatment"
        }, 
        "brief_summary": {
            "textblock": "A prospective,  multicenter, interventional study to collect confirmatory evidence on the\n      safety and effectiveness of the TactiCath\u00ae percutaneous ablation catheter for the treatment\n      of symptomatic paroxysmal atrial fibrillation using contact force assisted irrigated\n      radiofrequency ablation."
        }, 
        "brief_title": "TactiCath\u00ae Contact Force Ablation Catheter Study for Atrial Fibrillation Continued Access Protocol", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Paroxysmal Atrial Fibrillation", 
        "condition_browse": {
            "mesh_term": "Atrial Fibrillation"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  symptomatic PAF (Paroxysmal Atrial Fibrillation)refractory to at least one Class I-IV\n             antiarrhythmic drug\n\n          -  minimum one documented PAF episode >30 sec duration within prior 12 months\n\n          -  minimum three PAF episodes during prior 12 months\n\n          -  18 years or older\n\n        Exclusion Criteria:\n\n          -  persistent or long-standing persistent AF(Atrial Fibrillation)\n\n          -  four or more cardioversions in prior 12 months\n\n          -  MI (myocardial infarction), CABG (coronary artery bypass graft) or PCI (percutaneous\n             coronary intervention) within preceding 3 months\n\n          -  left atrial diameter > 5.0 cm\n\n          -  LVEF (left ventricular ejection fraction)< 35%\n\n          -  NYHA (New York Heart Association) class III or IV\n\n          -  previous left atrial ablation procedure\n\n          -  previous tricuspid or mitral valve repair surgery"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02088606", 
            "org_study_id": "VP-002 527 Version H"
        }, 
        "intervention": {
            "arm_group_label": "TactiCath Quartz", 
            "description": "Catheter ablation for the treatment of paroxysmal atrial fibrillation", 
            "intervention_name": "TactiCath Quartz treatment", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Atrial fibrillation", 
        "lastchanged_date": "March 13, 2014", 
        "location": {
            "contact": {
                "email": "ssayeed@partners.org", 
                "last_name": "Sabina Sayeed"
            }, 
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02114"
                }, 
                "name": "Massachusetts General Hospital"
            }, 
            "investigator": {
                "last_name": "Moussa Mansour, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "overall_contact": {
            "email": "nglowacki@sjm.com", 
            "last_name": "Nicole Glowacki", 
            "phone": "6517563432"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Electrical isolation of all 4 PVs, or in the event of a common PV, the clinical equivalent of all PVs, by the end of index procedure", 
                "safety_issue": "No", 
                "time_frame": "30 min post ablation"
            }, 
            {
                "measure": "Acute procedural success and freedom from recurrence of symptomatic AF, AFL, and AT lasting longer than 30 seconds through 9 months of follow-up after a 3 month blanking period. Re-treatment for AF with ablation after 3 months is a failure", 
                "safety_issue": "No", 
                "time_frame": "12 months post ablation"
            }, 
            {
                "measure": "Device-related early onset primary SAEs occurring within 7 days of the index procedure", 
                "safety_issue": "Yes", 
                "time_frame": "7 days post ablation"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02088606"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "St. Jude Medical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "St. Jude Medical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}